ABM Respiratory Care (ABMRC), based in India, a medical technology company involved in the airway declaration and ventilation, announced the closing of its series B financing round, which raised $ 14.8 million, $ 2.8 million above $ 12 million.
Peter Soderberg, ABMRC’s chairman of the Board of Directors and managing partner of Worthy Venture Resources, led the exceeded round, with the participation of Blue Wave Capital, in addition to new and existing investors.
What it does
Biwaze Clear, the airway control system of ABM Respiratory Care, helps people erase mucus and open airways.
According to the company, the saline solution provides thin mucus, makes the use of air tulses and vibrations to move mucus from the lungs and offers stable, accurate pressure to help open airways. It also reduces the spread of aeros roll particles outside the closed system. The system can be used at home or in a hospital environment.
The funds will be used to increase the commercialization of Biwaze Clear, to scale American sales initiatives, invest in clinical research and to increase the involvement of patients and digital health opportunities.
“This investment marks a crucial moment for ABM -while we expand access to our breathing therapy platform and bring transformative solutions in more houses and hospitals,” said Greg Miller, CEO of ABMRC, in a statement.
“We are grateful for the support of our new and existing investors who are enthusiastic about our vision of intelligent, connected therapies of people who have difficulty breathing.”
Market Snapshot
In 2024, ABM received extensive FDA 510 (K) clearance for its Biwaze Clear System for use with a fan in acute care environments.
The extensive indication presented acute healthcare institutions with a therapeutic option for ventilated patients with atelectase (a collapsed lung), retained secretions or pneumonia.
Other players in the room for respiratory care are established in Taiwan FaceHeart, which in the US in the US, obtained regulatory approval for its AI-driven contactless technology for measuring the respiratory speed.
It obtained a 510 (K) statement of the FDA for the respiratory speed measurement component of its software development kit.
FaceHeart offers a software development kit that uses the camera of a smartphone to capture vital signs, including heart rate, respiratory speed, blood pressure, oxygen saturation and heart rate variability.
The South Korean Ministry of Food and Drug Safety was approved in 2024 Easybreath by Share and Service, which helps with respiratory rehabilitation.
Easybreath by Share and Service is a mobile application that offers an eight -week respiratory rehabilitation program for people with chronic obstructive pulmonary disease, asthma and lung cancer. It is intended to reduce breathlessness and at the same time improve the aerobic capacity of a user.
#ABM #Alumhalingszorg #protects #million #airways #system